C212H350N56O78S · 4963 g/mol · PubChem CID 45382195 ↗
TB-500
also known as Thymosin Beta-4, TB4, Tβ4, thymosin β4
Synthetic 17-amino-acid fragment of human thymosin β4 (TMSB4X), itself a 43-residue actin-sequestering protein abundant in platelets, white blood cells, and many other tissues. Promotes endothelial cell migration, blood vessel development, and accelerated wound re-epithelialization across animal models and Phase 2 trials.
- Class
- Actin-sequestering peptide
- Evidence level
- Phase 2 clinical
- Regulatory status
- Not FDA-approved (US) — research use only
At a glance
SQ or IM · Multiple sites · 2–3×/week
Primary target — G-actin (sequestering) + cell-surface integrins [goldstein-2012].
Pathway — Actin remodelling → cell migration; integrin-linked signaling → angiogenesis; anti-inflammatory cytokine modulation [goldstein-2012][malinda-1999].
Downstream effect — Accelerated wound healing, endothelial migration, hair follicle regeneration, cardiac repair (preclinical) [goldstein-2012].
Origin — 17-AA active fragment of endogenous 43-AA thymosin β4 (TMSB4X gene).
Feedback intact — Endogenous protein at baseline; supplementation amplifies.
| Parameter | Value |
|---|---|
| Standard dose | 2 mg per injectionAnecdotal community range; clinical Phase 2 trials used 70–840 mcg/kg IV. |
| Frequency | 2× per week (loading); then 1× per week (maintenance) |
| Lower / starter dose | 1 mg per injection |
| Evidence basis | Animal-strong + Phase 2 dermal/ocular trials |
| Duration | 4–8 weeks loading; longer maintenance for chronic injury |
| Reconstitution | Bacteriostatic water, 1–2 mL per 5 mg vial |
| Timing | Evening or pre-rest preferred (anecdotal) |
| Half-life | ~2 hours (estimated; tissue uptake longer) |
Reconstitution
A pure mass-to-volume utility. Enter what you have in the vial; the atlas computes the volume per dose. No prescription information.
Lab verification
Third-party lab reports tied to batch codes, re-verifiable at the issuing lab. A fact and where to re-check it — never a verdict.
- — Active malignancy (theoretical angiogenesis concern)
- — Pregnancy / breastfeeding
- — Cancer history
- — Concurrent VEGF inhibitor therapy
- 01Reconstitution
Add 1–2 mL bacteriostatic water to 5 mg vial → 2.5–5 mg/mL. Roll gently.
- 02Injection site
SQ near injury site (preferred), or systemic SQ (abdomen). Rotate sites.
- 03Timing
Evening or pre-sleep is most common anecdotal timing.
- 04Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate, ≤30 days.
- 05Needle
27–31G, 4–8 mm insulin syringe.
Frequently asked
How does TB-500 work?
TB-500 acts on G-actin (sequestering) + cell-surface integrins, signalling via Actin remodelling → cell migration; integrin-linked signaling → angiogenesis; anti-inflammatory cytokine modulation. [goldstein-2012][goldstein-2012][malinda-1999]
Is TB-500 FDA-approved?
TB-500 is not FDA-approved in the United States and is handled as a research compound (research use only). Regulatory status may differ in other jurisdictions.
Sources
of 46 rendered claims carry a resolvable citation.
- [goldstein-2012]Goldstein 2012 — Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications
Expert Opin Biol Ther, 2012
Mechanism + clinical trial review for TB-500 / Thymosin β4. - [malinda-1999]Malinda 1999 — Thymosin beta4 accelerates wound healing
J Invest Dermatol, 1999
Murine wound-healing model — TB-500 accelerates re-epithelialization.